Unmet needs, uncommon commitment: The shift toward investment in rare diseases

January 19, 2017 Erin Righetti

 

 

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease drug discovery and development. The panel discuss how approaches to rare disease research, drug development, commercialization and investment have changed in recent years, and why and how they’ve chosen to pursue leadership and innovation in rare diseases.

Moderator: Alison Silva – Critical Outcome Technologies

  • Debra Miller – CureDuchenne
  • Henri Termeer – Formerly Genzyme; Aura Biosciences
  • Phil Vickers – Shire
  • Flemming Ornskov – Shire

About the Author

Erin Righetti

Editor-in-Chief, Insight

Follow on Twitter More Content by Erin Righetti
Previous Article
Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017
Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporter...

Next Video
#DigMedShow & #MedtechShow 2017: Verily, Qualcomm, Proteus, Johnson & Johnson, Hogan Lovells
#DigMedShow & #MedtechShow 2017: Verily, Qualcomm, Proteus, Johnson & Johnson, Hogan Lovells

A holistic approach is critical to creating viable solutions for an efficient and effective healthcare syst...